Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition
The Journal of Physical Chemistry B · 2025
DOI: 10.1021/acs.jpcb.4c07960 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, 2025. Verfasst von Neel Shanmugam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of North Texas, Denton, Texas 76201, United States. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Poly(ADP-ribose) polymerase1 (PARP1) plays a vital role in DNA repair, and its inhibition in cancer cells may cause cell apoptosis. In this study, we investigated the effects of a PARP1 variant, V762A, which is strongly associated with several cancers in humans, on the inhibition of PARP1 by three FDA-approved inhibitors: niraparib, rucaparib, and talazoparib. Specifically, we compared the inhibition of the mutant to that of wild-type (WT) PARP1. Additionally, we investigated how the mutation influences the binding of these inhibitors to PARP1. Our work suggests that while mutant PARP1 exhibits only minor differences in residual fluctuations, backbone deviations, and residue motion correlations compared to the WT under niraparib and rucaparib inhibitions, it shows significant and distinct differences in these features when inhibited by talazoparib. Among the three inhibitions, talazoparib inhibition uniquely lowers the average residue fluctuations in the mutant than the WT including lower fluctuations of mutant's N- and C-terminal residues in the catalytic domain, conserved H-Y-E traid residues, and donor loop (D-loop) residues which are important for catalysis more effectively than other inhibitions. However, talazoparib also significantly enhances destabilizing interactions between the mutation site in the HD domain in the mutant than WT. Further, among the three inhibitions, talazoparib inhibition uniquely and significantly disrupts the functional fluctuations of terminal regions in the mutant, which are otherwise present in the WT. The mutation and inhibition do not significantly affect PARP1's essential dynamics. Lastly, these inhibitors bind to the V762A mutant more effectively than to the WT, with similar binding free energies between them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of North Texas, Denton, Texas 76201, United States.
- Department of Chemistry and Biochemistry, University of Texas at Dallas, Richardson, Texas 75080, United States.
- Department of Physics, University of Texas at Dallas, Richardson, Texas 75080, United States.
ORCID-Profile: G Andrés Cisneros
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Shanmugam, N., Chatterjee, S., & Cisneros, G. A. (2025). Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.4c07960
Vancouver
Shanmugam N, Chatterjee S, Cisneros GA. Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition. The Journal of Physical Chemistry B. 2025. doi:10.1021/acs.jpcb.4c07960
BibTeX
@article{Shanmugam2025,
author = {Shanmugam, Neel and Chatterjee, Shubham and Cisneros, G Andrés},
title = {Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition},
journal = {The Journal of Physical Chemistry B},
year = {2025},
doi = {10.1021/acs.jpcb.4c07960}
}
EUVIMED